TPX-0046
TPX-0046 is a next-generation RET kinase inhibitor developed to target tumors resistant to first-generation agents like selpercatinib and pralsetinib. It is a research tool for investigating resistance mechanisms and evaluating novel therapeutic strategies in both in vitro and in vivo models of RET-driven cancers.
Product Specifications
CAS Number
2359650-19-2
Product Name Alternative
RET, TPX 0046, TPX0046, TPX-0046, cRET
Field of Research
Cardiovascular Research, Cell Biology, Signal Transduction
Purity
99.07% (May vary between batches)
Solubility
DMSO:2 mg/mL (4.71 mM)
Smiles
FC=1C=C2CN3C=4C (=CN5C (N4) =C (C=N5) C (=O) NC[C@@H] (C) OC2=NC1) O[C@]6 ([C@@]3 (CCC6) [H]) [H]
Molecular Formula
C21H21FN6O3
Molecular Weight
424.43
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
TP301765M 100 µg
p21 (CDKN1A) (NM_078467) Human Recombinant Protein
Sign In for Pricing
View Details 
35343091 4x 500 ng
OR52L2P-set siRNA/shRNA/RNAi Lentivector (Human)
Sign In for Pricing
View Details DZ41495-PE 200 µL/Vial
Anti-Strongyloides ratti Metalloendopeptidase Antibody, PE Conjugate
Sign In for Pricing
View Details 
LV657697 1.0 µg DNA
GRAMD3 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)
Sign In for Pricing
View Details